Idelalisib inhibits experimental proliferative vitroretinopathy.
Dong L, Han H, Huang X, Ma G, Fang D, Qi H, Han Z, Wang L, Tian J, Vanhaesebroeck B, Zhang G, Zhang S, Lei H.
Dong L, et al. Among authors: vanhaesebroeck b.
Lab Invest. 2022 Dec;102(12):1296-1303. doi: 10.1038/s41374-022-00822-7. Epub 2022 Jul 19.
Lab Invest. 2022.
PMID: 35854067
Free article.